This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Sarcoma 180
Information about Sarcoma 180: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Sarcoma 180
Most recent studies have shown that Sarcoma 180 shares some biological mechanisms with adenocarcinoma, carcinoma, carcinoma-256-walker, carcinoma-ehrlich-tumor, leukemia, leukemia-experimental, leukemia-l1210, liver-carcinoma, lung-neoplasms, malignant-neoplasm-of-lung, malignant-neoplasms, mammary-neoplasms-experimental, melanoma, neoplasms, neoplasms-experimental, sarcoma, sarcoma-experimental, solid-tumor.
Among the many pathways, these few ones have gauged particular interests from scientists studying Sarcoma 180, and have been seen in publications frequently: Angiogenesis, Cell Cycle, Cell Death, Cell Growth, Cell Killing, Cell Proliferation, Drug Resistance, Excretion, Fermentation, Hypersensitivity, Immune Response, Induction Of Apoptosis, Localization, Lymphocyte Proliferation, Methylation, Mitosis, Phagocytosis, S Phase, Secretion, Transport
Quite a number of genes have been found to play important roles in Sarcoma 180, such as ADM, ALB, BCL2, C3, CALM2, CAT, CYP27A1, DHFR, ERMAP, HGF, IFNG, IL2, IL6, SOD1, TF, TG, TNF, TYMS, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.